Bank of New York Mellon Corp Has $3.95 Million Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Bank of New York Mellon Corp increased its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 37.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 201,201 shares of the company’s stock after purchasing an additional 55,020 shares during the period. Bank of New York Mellon Corp owned about 0.67% of Fulgent Genetics worth $3,948,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. TCW Group Inc. increased its holdings in Fulgent Genetics by 3.0% in the 2nd quarter. TCW Group Inc. now owns 120,100 shares of the company’s stock valued at $2,356,000 after buying an additional 3,500 shares during the period. SG Americas Securities LLC increased its stake in Fulgent Genetics by 36.4% in the second quarter. SG Americas Securities LLC now owns 12,826 shares of the company’s stock valued at $252,000 after acquiring an additional 3,425 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Fulgent Genetics by 32.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,261 shares of the company’s stock valued at $310,000 after acquiring an additional 3,458 shares during the period. EntryPoint Capital LLC raised its position in Fulgent Genetics by 15,067.0% in the first quarter. EntryPoint Capital LLC now owns 15,622 shares of the company’s stock worth $339,000 after purchasing an additional 15,519 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its stake in Fulgent Genetics by 11.0% during the first quarter. CANADA LIFE ASSURANCE Co now owns 29,103 shares of the company’s stock worth $631,000 after purchasing an additional 2,879 shares during the period. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Trading Up 1.5 %

NASDAQ FLGT opened at $22.35 on Friday. Fulgent Genetics, Inc. has a 1-year low of $18.91 and a 1-year high of $30.68. The stock’s 50 day moving average is $22.67 and its two-hundred day moving average is $21.72. The company has a market capitalization of $677.21 million, a price-to-earnings ratio of -4.01 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings results on Friday, August 2nd. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. The firm had revenue of $71.03 million for the quarter, compared to analysts’ expectations of $69.07 million. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. The business’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share. On average, analysts predict that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current year.

Insider Buying and Selling

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the sale, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at $16,147,088.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 4,324 shares of company stock worth $98,717 in the last quarter. 31.76% of the stock is owned by corporate insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.